Skip to main content
Marksans Pharma Ltd. logo

Marksans Pharma Ltd. — Investor Relations & Filings

Ticker · MARKSANS ISIN · INE750C01026 LEI · 335800YXQPMPSAC51K30 BSE.NS Manufacturing
Open in API
Filings indexed 743 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country IN India
Listing BSE.NS MARKSANS

About Marksans Pharma Ltd.

https://www.marksanspharma.com

Marksans Pharma Ltd. specializes in the research, development, and large-scale manufacturing of generic formulations. The company’s therapeutic focus spans pain management, cardiovascular health, central nervous system disorders, anti-diabetics, and gastrointestinal treatments. Its product portfolio includes diverse delivery systems such as solid orals, soft gelatin capsules, and liquid formulations, serving both the over-the-counter and prescription markets. The organization operates advanced manufacturing facilities compliant with international regulatory standards, facilitating a robust supply chain across major global markets including North America, Europe, and Australia. By integrating comprehensive research and development with efficient production processes, the company provides a broad range of high-quality, cost-effective medicinal products to a global patient base.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 87% confidence The document is a notice to stock exchanges under SEBI Listing Regulations informing them that the audio recording of an investor/analyst conference call on Q4 FY26 financial results has been uploaded to the company website. It does not contain actual financial data, management discussion, or Q&A transcript, nor is it the report itself. Instead, it's a general regulatory announcement required by listing obligations. Therefore it fits the Regulatory Filings category (RNS).
2026-05-27 English
Audio Recording of investor(s) / analyst(s) meet Conference Call on Q4 FY26 Financial Results
Regulatory Filings Classification · 75% confidence The document is a formal stock exchange notice pursuant to SEBI Listing Regulations informing that the audio recording of an investor/analyst conference call on Q4 FY26 financial results has been uploaded to the company website. It does not include financial data, the report itself, or a transcript, but is a compliance announcement to regulators. This falls under general regulatory filings (RNS).
2026-05-27 English
Copy of Newspaper Publication
Earnings Release Classification · 85% confidence The document is an official notice to the stock exchanges (BSE & NSE) under SEBI Listing Regulations, enclosing copies of a newspaper advertisement that publishes the “Audited Financial Results for the quarter and year ended March 31, 2026.” It includes summary tables of key metrics (total income, net profit, comprehensive income, EPS) and refers readers to full formats on the company and exchange websites. This is the initial public announcement of periodic financial results (not the full annual report), matching the definition of an Earnings Release. FY 2026
2026-05-27 English
Newspaper publication of Audited Financial Results for the financial year ended 31 March, 2026
Report Publication Announcement Classification · 85% confidence The document is a letter from Marksans Pharma to the BSE and NSE notifying them that the audited financial results for the quarter and year ended March 31, 2026 have been published as newspaper advertisements. It does not contain the full financial statements or substantive data itself but merely announces publication of the report in newspapers (Regulation 47 SEBI LODR). Under the “menu vs. meal” rule, this is an announcement of publication rather than the actual results, so it should be classified as a Report Publication Announcement (RPA).
2026-05-27 English
ASCR under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year 31, March 2026
Regulatory Filings Classification · 72% confidence The document is a letter filed with stock exchanges under SEBI LODR Regulation 24A attaching the Annual Secretarial Compliance Report for the year ended March 31, 2026. It is a compliance certificate/report rather than a full Annual Report (10-K), financial statements, earnings release, or management discussion. It does not introduce corporate governance policy per se but serves as a regulatory compliance filing. There is no dedicated category for secretarial compliance reports, so it falls under the general Regulatory Filings fallback category.
2026-05-27 English
The Board has recommended Dividend of Rs. 0.90 per share subject to approval of Shareholders at ensuing Annual General Meeting
Regulatory Filings Classification · 85% confidence The document is a formal announcement to the stock exchanges under SEBI Listing Regulations (Regulation 33/30) of Marksans Pharma’s audited financial results for the quarter and full year ended March 31, 2026, including the Independent Auditor’s Report. It is not a full Annual Report (10-K) nor a shortened earnings release (ER), nor an interim/quarterly report (IR) because it covers the full fiscal year and includes detailed audited results and audit opinion. It is also not merely a publication notice (RPA) but the actual regulatory filing of audited financial results. Therefore, it best fits into the general Regulatory Filings category (RNS).
2026-05-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.